Allogeneic tumor cell vaccine(Mayo Clinic)(Allogeneic tumor cell vaccine(Mayo Clinic))

概要

基本信息

药物类型

治疗性疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症-

非在研适应症

去势抵抗性前列腺癌非转移性前列腺癌

原研机构

Mayo Clinic

在研机构-

非在研机构

Mayo Clinic

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 Allogeneic tumor cell vaccine(Mayo Clinic) 相关的临床试验

NCT00814892

/ Terminated临床2期IIT

A Phase II Trial to Determine the Safety, Tolerability and Efficacy of an Allogeneic Whole Cell Vaccine Administered With Autologous Myeloid Dendritic Cells to Patients With Non-Metastatic Androgen Independent Prostate Carcinoma

RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer.
PURPOSE: This phase II trial is studying how well the combination of a proven effective allogenic whole prostate carcinoma cell (APCC) vaccine co-administered with ex vivo generated dendritic cells (DCs)(DC-APCC) extend the time to prostate cancer progression.

开始日期2009-01-01

申办/合作机构

Mayo Clinic

[+1]

100 项与 Allogeneic tumor cell vaccine(Mayo Clinic) 相关的临床结果

登录后查看更多信息

100 项与 Allogeneic tumor cell vaccine(Mayo Clinic) 相关的转化医学

登录后查看更多信息

100 项与 Allogeneic tumor cell vaccine(Mayo Clinic) 相关的专利（医药）

登录后查看更多信息

100 项与 Allogeneic tumor cell vaccine(Mayo Clinic) 相关的药物交易

登录后查看更多信息